Strides oncology facility gets US FDA approval
02 May 2011
Generic drugs maker Strikes Arcolab today said that its Bangalore-based oncology facility, Onco Therapies Limited (OTL), has received approval from the US FDA.
The company said the critical approval would help Onco Therapies, a division of its wholly-owned subsidiary Agila Specialities, would enable it to enhance its preence in the oncology segment.
Strides had recently announced having receiovved US FDA approval for its non-oncology sterile facility in Bangalore.
With these approvals, all of Strides' 5 sterile plants in India are now US FDA approved.
"Consequent to the approval, Strides expects to begin receiving ANDA approvals for oncology products for which filings have already been made," Strides said in an official announcement.
Agila CEO Venkat Iyer said in the statement, ''With this approval and the recently announced approval for the Sterile Complex, we now look forward to scaling up our specialty business through the launch of highly specialised products for the US market.''
Strides said it was well positioned to build a distinct identity for itself in the industry.
